Gastrointestinal Cancer

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

The NAPOLI 3 trial demonstrated that NALIRIFOX improved outcomes for patients with metastatic pancreatic ductal adenocarcinoma compared with the standard of care, nab-paclitaxel and gemcitabine.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventive measures and a collaboration with dermatology.

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.

Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

Results from the PEAK trial showed increased PFS in the bezuclastinib plus sunitinib arm vs sunitinib alone for patients with GIST.

Data from the phase 2 INTERACT-ION trial support further investigation of the potential synergistic effect of ezabenlimab plus adaptive chemoradiotherapy.

Micheal C. Soulen, MD, spoke about his presentation on the CapTemY90 trial at the 2025 NANETS Multidisciplinary NET Medical Symposium.

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.

The safety profile of lenvatinib/pembrolizumab plus TACE among patients with unresectable HCC was consistent with previously reported studies.

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.

The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.